hero image

Biogen Idec Announces March 25 Webcast of Research & Development Day

March 18, 2009 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ:BIIB) announced today that it will hold its 2009 R&D Day on Wednesday, March 25, 2009 from 1 PM ET to 5 PM ET. Dr. Cecil Pickett, Biogen Idec's President of Research & Development, along with members of the Company's R&D leadership team will provide a detailed review of the Company's pipeline programs.

Media, investors and the general public can access the live event by visiting the "Investor" section of the Biogen Idec web site, investor.biogenidec.com. Audio and slide presentations will be available through the web site. An archived version of the webcast will be available for 30 days following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

Biogen Idec
Investor Relations
Rob Jacobson, 617-679-2812

thumb
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human

thumb
April 24, 2024
Biogen Reports First Quarter 2024 Results